Eric Singhi/faculty.mdanderson.org
Apr 2, 2025, 07:50
Eric Singhi: How MARIPOSA and MARIPOSA-2 studies differ
Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Getting great questions from patients with EGFR+ lung cancer about the MARIPOSA and MARIPOSA 2 studies after ELCC 25, and how they differ.
What else should we add to this table to make it more helpful?”
Related to this article:
MARIPOSA trial results presented at ELCC25 – BREAKING from Paris
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 17:03
Jun 8, 2025, 16:53